However, none of these approaches have been clinically applied (74) The present study now offers new alternative solutions either by transcriptional perturbation or by disrupting the cooperation between E2F1 and the coregulator, in this case STAT3, which has the potential to rescue a cancer-refusing immune response by rebalancing the TME and removing prometastatic properties. The gene discussed is E2F1; the disease is cancer.